Is AI patentable?

5 July 2022

An Expert View from Robert Sackin, a chartered and European patent attorney, and partner at Reddie & Grose.

It goes without saying that artificial intelligence (AI) is now everywhere, especially in the life sciences sector. In this field, it is used for a wide range of different purposes from cost analysis to drug discovery.

Life science firms employing AI technologies are seen as very attractive investment opportunities. However, to secure the value of innovative AI, the firm may wish to seek patent protection for it. There is a lot of mystery over whether AI is patentable and there is a good reason for this. AI might be patentable. It depends on the specific AI invention.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK